Primary prevention of beta-cell autoimmunity and type 1 diabetes - The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives
详细信息 查看全文
- 作者：A.G. Ziegler1 ; 2 ; anette-g.ziegler@helmholtz-muenchen.de" class="auth_mail" title="E-mail the corresponding author ; T. Danne3 ; D.B. Dunger4 ; R. Berner5 ; R. Puff1 ; W. Kiess6 ; G. Agiostratidou7 ; J.A. Todd8 ; E. Bonifacio9
- 关键词：Type 1 diabetes ; Beta-cell autoimmunity ; Prevention ; Antigen-based immunotherapy
- 刊名：Molecular Metabolism
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：5
- 期：4
- 页码：255-262
- 全文大小：852 K
文摘
- •
GPPAD is a new type 1 diabetes prevention initiative in Europe.
- •
GPPAD will provide infrastructure for trials to reduce beta-cell autoimmunity.
- •
An adaptable GPPAD trial with antigen-based therapy is modeled.
- •
GPPAD will provide new opportunities for mechanistic and observational studies.